

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3998458

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	PROSTAGENE, LLC	08/09/2016
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	RICHARD G. PESTELL	
<b>Street Address:</b>	901 N. PENN ST.	
<b>City:</b>	PHILADELPHIA	
<b>State/Country:</b>	PENNSYLVANIA	
<b>Postal Code:</b>	19123	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	13893791
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(610)640-7835	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	610-640-7820	
<b>Email:</b>	bwdocket@pepperlaw.com	
<b>Correspondent Name:</b>	DANIEL M. SCOLNICK	
<b>Address Line 1:</b>	PEPPER HAMILTON LLP	
<b>Address Line 2:</b>	899 CASSATT ROAD	
<b>Address Line 4:</b>	BERWYN, PENNSYLVANIA 19312	
<b>ATTORNEY DOCKET NUMBER:</b>	140993.00201	
<b>NAME OF SUBMITTER:</b>	MELISSA SEEBARAN	
<b>SIGNATURE:</b>	/Melissa Seebaran/	
<b>DATE SIGNED:</b>	08/09/2016	
<b>Total Attachments: 6</b>		
source=Assignment_Prostagene_to_Pestell#page1.tif		
source=Assignment_Prostagene_to_Pestell#page2.tif		
source=Assignment_Prostagene_to_Pestell#page3.tif		
source=Assignment_Prostagene_to_Pestell#page4.tif		
source=Assignment_Prostagene_to_Pestell#page5.tif		



## PATENT RIGHTS ASSIGNMENT

This Patent Rights Assignment (this "Assignment") is made effective this 9th day of August, 2016, by and between **PROSTAGENE, LLC**, a limited liability corporation organized and existing under the laws of Delaware ("Assignor"), with its principal place of business at Lankenau Institute for Medical Research, 100 Lancaster Avenue, Room 129A, Wynnewood, PA 19096, and **RICHARD PESTELL**, an individual ("Assignee").

WHEREAS, Assignee had previously and inadvertently assigned to Assignor all rights in and to the patents and patent applications (and patents issuing on such applications, as applicable) set forth on Exhibit A attached hereto and incorporated herein by reference (collectively, the "Patent Rights") and the invention(s) described and/or claimed in the Patent Rights (the "Inventions");

WHEREAS, Assignor still possesses all rights in and to the Inventions and Patent Rights; and

WHEREAS, Assignor now wishes to assign back the Inventions and Patent Rights to Assignee, and Assignee desires to acquire the Inventions and Patent Rights from Assignor.

NOW, THEREFORE, in consideration of the premises set forth above and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged:


Assignor does hereby sell, assign, convey and transfer unto Assignee and his successors, assigns, and legal representatives, Assignor's entire right, title and interest in and throughout the world in and to the Inventions, together with Assignor's entire right, title and interest in and to the Patent Rights and such other patents as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, continuations-in-parts, divisionals, reissues, reexaminations, reviews, extensions, and substitutions of patents and patent applications within the Patent Rights or such other patents, and any right, title and interest Assignor may have in applications to which the Patent Rights claim priority; the Inventions and the Patent Rights to be held and enjoyed by Assignee for his own use and behalf and for his successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made; and Assignor hereby conveys all of its rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property including but not limited to the right to bring any cause(s) of action and damages for past, present and future infringement or other violation thereof. Assignor hereby acknowledges that this assignment, being of Assignor's entire right, title and interest in and to the Inventions and the Patent Rights carries with it the right in Assignee to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of Assignee's selection and the right to procure the grant of all patents to Assignee in his own name as assignee of Assignor's entire right, title and interest therein.

Assignor does hereby authorize the Director of the United States Patent & Trademark Office, and the empowered officials of all other governments whose duty it is to record patents, applications and title thereto, to record the Patent Rights and title thereto as the property of Assignee, his successors, assigns, or legal representatives in accordance with the terms of this instrument.

Assignor does hereby further authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Patent Rights or patents as shall be granted upon the Patent Rights, or applications based thereon, to Assignee, his successors, assigns, or legal representatives.

Assignee and Assignor also agree that multiple copies of this Assignment may be executed, each of which shall be deemed an original, and each of which shall be valid and binding upon Assignee and Assignor.

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the date first written above.

ASSIGNOR:	<b>PROSTAGENE, LLC</b>
Name:	Richard Pestell
Signature:	
Title:	President


ASSIGNEE:	<b>RICHARD PESTELL</b>
Signature:	

Exhibit A

PATENT RIGHTS

Title	Country	Application No.	Filing Date
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF	US	61/646,586	May 14, 2012
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF	US	61/646,593	May 14, 2012
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF	US	13/893,791	May 14, 2013
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF	PCT	PCT/US2013/040917	May 14, 2013
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF	AU	2013262977	May 14, 2013
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF	CA	2873743	May 14, 2013
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF	CN	201380037638.6	May 14, 2013

Title	Country	Application No.	Filing Date
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF	EP	13790117.9	May 14, 2013
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF	HK	15110378.4	May 14, 2013
PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF	JP	2015-512749	May 14, 2013
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	US	61/450,767	March 9, 2011
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	US	14/003,384	November 19, 2013
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	PCT	PCT/US2012/028546	March 9, 2012
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	AU	2012225232	March 9, 2012

Title	Country	Application No.	Filing Date
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	BR	BR112013023050-9	March 9, 2012
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	CA	2829219	March 9, 2012
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	CN	201280020337.8	March 9, 2012
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	EP	12755544.9	March 9, 2012
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	HK	14107239.0	March 9, 2012
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	IN	7885/DELNP/2013	March 9, 2012
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	JP	2013-557917	March 9, 2012

*Exhibit A to Patent Rights Assignment*

Title	Country	Application No.	Filing Date
USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS	MX	MX/A/2013/010330	March 9, 2012